Business Description
Fractyl Health Inc
NAICS : 541714
SIC : 2834
ISIN : US35168W1036
Total Employee Number:
73Description
Fractyl Health Inc is a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D). Its Revita and Rejuva candidates are designed to target root causes of metabolic diseases, allowing the company to advance metabolic disease treatment from chronic management towards prevention and reversion of the disease. The Revita DMR System (Revita), its lead product candidate, is based on its insights surrounding the potential role of the gut in obesity.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.78 | |||||
Equity-to-Asset | -0.02 | |||||
Debt-to-Equity | -36.48 | |||||
Debt-to-EBITDA | -0.72 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -28.6 | |||||
3-Year EPS without NRI Growth Rate | -33 | |||||
3-Year FCF Growth Rate | -28.7 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 37.04 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 47.52 | |||||
9-Day RSI | 48.54 | |||||
14-Day RSI | 48.43 | |||||
3-1 Month Momentum % | -10.89 | |||||
6-1 Month Momentum % | 34.05 | |||||
12-1 Month Momentum % | -27.45 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.15 | |||||
Quick Ratio | 3.15 | |||||
Cash Ratio | 3 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -47.7 | |||||
Shareholder Yield % | -73.82 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -6789.85 | |||||
ROA % | -110.27 | |||||
ROIC % | -216.47 | |||||
3-Year ROIIC % | -162 | |||||
ROC (Joel Greenblatt) % | -293.95 | |||||
ROCE % | -110.39 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
EV-to-EBIT | -1.43 | |||||
EV-to-Forward-EBIT | -1.59 | |||||
EV-to-EBITDA | -1.45 | |||||
EV-to-Forward-EBITDA | -1.59 | |||||
EV-to-Forward-Revenue | 3 | |||||
EV-to-FCF | -1.49 | |||||
Earnings Yield (Greenblatt) % | -69.93 | |||||
FCF Yield % | -75.35 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:GUTS
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Fractyl Health Inc Executives
DetailsGF Value™
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.095 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 128.26 | ||
| 14-Day RSI | 48.43 | ||
| 14-Day ATR ($) | 0.06285 | ||
| 20-Day SMA ($) | 0.706405 | ||
| 12-1 Month Momentum % | -27.45 | ||
| 52-Week Range ($) | 0.3772 - 2.445 | ||
| Shares Outstanding (Mil) | 159.18 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Fractyl Health Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Fractyl Health Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-12 16:30 | In 71 days | ||
| Third quarter earnings results for 2026 | 2026-11-12 | In 70 days | ||
| Fractyl Health Virtual Commercial Strategy Day: The Potential Path to Commercializing Revita®, a Procedural Therapy for Post-GLP-1 Weight Maintenance | 2026-09-01 11:00 | 0.71 (+4.53%) | ||
| Canaccord Genuity 46th Annual Growth Conference | 2026-08-12 08:30 | 0.70 (+9.66%) | ||
| Second quarter earnings conference call for 2026 | 2026-08-10 16:30 | 0.70 (+0.37%) | ||
| Second quarter earnings results for 2026 | 2026-08-10 | 0.70 (+0.37%) | ||
| General meeting for 2026 | 2026-06-10 12:00 | 0.66 (-1.67%) | ||
| Guidance call for 2026 | 2026-05-14 12:20 | 0.95 (+20.80%) | ||
| First quarter earnings conference call for 2026 | 2026-05-12 16:30 | 0.77 (-1.32%) | ||
| First quarter earnings results for 2026 | 2026-05-12 | 0.77 (-1.32%) |
Show
Entries
Fractyl Health Inc Frequently Asked Questions
What is Fractyl Health Inc(GUTS)'s stock price today?
The current price of GUTS is $0.69. The 52 week high of GUTS is $2.44 and 52 week low is $0.38.
When is next earnings date of Fractyl Health Inc(GUTS)?
The next earnings date of Fractyl Health Inc(GUTS) is 2026-11-12 Est..
Does Fractyl Health Inc(GUTS) pay dividends? If so, how much?
Fractyl Health Inc(GUTS) does not pay dividend.
Press Release
Articles on Fractyl Health Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers